In this study, we chose the catalytic mTOR inhibitor INK128 to compare with EtOH for the purpose of elucidating convergent and divergent pathways between the two treatments, in the context of DLBCL. This evidence concerns the gene MTOR and diffuse large B-cell lymphoma.